Gabriela Torrea

Instituut voor Tropische Geneeskunde — Belgium

Medicine · Health Sciences

24h-index3.2kcitations64works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Tuberculosis Research and Epidemiology(56), Mycobacterium research and diagnosis(36), Pneumocystis jirovecii pneumonia detection and treatment(12), Pneumonia and Respiratory Infections(9), Diagnosis and treatment of tuberculosis(9)

Publications61 total

Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial
The Lancet Respiratory Medicine·2024· 10 citedOpen Access
Rifampicin Resistance Conferring Mutations among Mycobacterium tuberculosis Strains in Rwanda
International Journal of Mycobacteriology·2023· 4 citedOpen Access
Strain diversity and gene mutations associated with presumptive multidrug-resistant Mycobacterium tuberculosis complex isolates in Northwest Ethiopia
Journal of Global Antimicrobial Resistance·2022· 10 citedOpen Access
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial
The Lancet·2022· 134 citedOpen Access
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB
The International Journal of Tuberculosis and Lung Disease·2022· 4 citedOpen Access
Keeping up with the guidelines: design changes to the STREAM stage 2 randomised controlled non-inferiority trial for rifampicin-resistant tuberculosis
Trials·2022· 8 citedOpen Access
Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings
JAC-Antimicrobial Resistance·2022· 8 citedOpen Access
Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases·2022· 10 citedOpen Access
Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases·2021Open Access
Effectiveness of GenoType MTBDR <i>sl</i> in excluding TB drug resistance in a clinical trial
The International Journal of Tuberculosis and Lung Disease·2021· 3 citedOpen Access
Discordance of the Repeat GeneXpert MTB/RIF Test for Rifampicin Resistance Detection Among Patients Initiating MDR-TB Treatment in Uganda
Open Forum Infectious Diseases·2021· 6 citedOpen Access
Rifampicin-Resistant Tuberculosis Control in Rwanda Overcomes a Successful Clone That Causes Most Disease Over a Quarter Century
SSRN Electronic Journal·2021Open Access
Discordance of the Repeat GeneXpert MTB/RIF test for Rifampicin Resistance Detection among Patients Initiating MDR-TB Treatment in Uganda
Research Square (Research Square)·2020Open Access
Genetic diversity of the Mycobacterium tuberculosis complex strains from newly diagnosed tuberculosis patients in Northwest Ethiopia reveals a predominance of East-African-Indian and Euro-American lineages
International Journal of Infectious Diseases·2020· 15 citedOpen Access
Management of falsepositive rifampicin resistant Xpert MTB/RIF – Authors' reply
The Lancet Microbe·2020Open Access
A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination
Antimicrobial Agents and Chemotherapy·2020· 14 citedOpen Access
Prevalence and drivers of false-positive rifampicin-resistant Xpert MTB/RIF results: a prospective observational study in Rwanda
The Lancet Microbe·2020· 61 citedOpen Access
Multidrug-resistant patients receiving treatment in Niger who are infected with M. tuberculosis Cameroon family convert faster in smear and culture than those with M. tuberculosis Ghana family
Tuberculosis·2020· 9 cited
Reduction of diagnostic and treatment delays reduces rifampicin-resistant tuberculosis mortality in Rwanda
The International Journal of Tuberculosis and Lung Disease·2020· 40 citedOpen Access
Validation of Bedaquiline Phenotypic Drug Susceptibility Testing Methods and Breakpoints: a Multilaboratory, Multicountry Study
Journal of Clinical Microbiology·2020· 39 citedOpen Access
page 1 of 4Next →

Frequent Co-authors

Armand Van Deun(20), Bouke C. de Jong(17), Leen Rigouts(16), Andrew Nunn(9), Sarah Meredith(8), I. D. Rusen(8), Conor J. Meehan(7), S. Bertel Squire(6), Tom Decroo(6), Chen‐Yuan Chiang(5), Ronelle Moodliar(5), Karen Sanders(5), Ruth Goodall(5), Brigitte Gicquel(5), Jean Claude Semuto Ngabonziza(5), Emmanuel André(5), Christel Desmaretz(5), Francesca Conradie(4), Nosipho Ngubane(4), Bazarragchaa Tsogt(4)